Disentangling Node Attributes from Graph Topology for Improved Generalizability in Link Prediction

Link prediction is a crucial task in graph machine learning with diverse applications. We explore the interplay between node attributes and graph topology and demonstrate that incorporating pre-trained node attributes improves the generalization power of link prediction models. Our proposed method, UPNA (Unsupervised Pre-training of Node Attributes), solves the inductive link prediction problem by learning a function that takes a pair of node attributes and predicts the probability of an edge, as opposed to Graph Neural Networks (GNN), which can be prone to topological shortcuts in graphs with power-law degree distribution. In this manner, UPNA learns a significant part of the latent graph generation mechanism since the learned function can be used to add incoming nodes to a growing graph. By leveraging pre-trained node attributes, we overcome observational bias and make meaningful predictions about unobserved nodes, surpassing state-of-the-art performance (3X to 34X improvement on benchmark datasets). UPNA can be applied to various pairwise learning tasks and integrated with existing link prediction models to enhance their generalizability and bolster graph generative models.

AI-Bind: Improving Binding Predictions for Novel Protein Targets and Ligands

Identifying novel drug-target interactions (DTI) is a critical and rate limiting step in drug discovery. While deep learning models have been proposed to accelerate the identification process, we show that state-of-the-art models fail to generalize to novel (i.e., never-before-seen) structures. We first unveil the mechanisms responsible for this shortcoming, demonstrating how models rely on shortcuts that leverage the topology of the protein-ligand bipartite network, rather than learning the node features. Then, we introduce AI-Bind, a pipeline that combines network-based sampling strategies with unsupervised pre-training, allowing us to limit the annotation imbalance and improve binding predictions for novel proteins and ligands. We illustrate the value of AI-Bind by predicting drugs and natural compounds with binding affinity to SARS-CoV-2 viral proteins and the associated human proteins. We also validate these predictions via auto-docking simulations and comparison with recent experimental evidence. Overall, AI-Bind offers a powerful high-throughput approach to identify drug-target combinations, with the potential of becoming a powerful tool in drug discovery.